The Phase I segment involves a dose escalation study of the therapy as a single agent and in conjunction with oral ...

nodes of MTAP-deletion bladder cancer pathway MTAP-deletion prevalence in bladder cancer is estimated to be approximately 26% IDEAYA will sponsor the clinical trial and Gilead will provide ...

The clinical collaboration with Amgen enables clinical evaluation of a potential first-in-class combination to inhibit two synthetic lethal nodes within the MTAP pathway – MAT2A and PRMT5 ...

Preclinical studies have identified synthetic lethal protein and metabolic interactions, recurrently overexpressed proteins, and frequent pathway perturbations that ... (NF2), methylthioadenosine ...

MTAP-null cells lack the ability to metabolize 5-methylthioadenosine, or MTA, which is an essential step in a biochemical pathway involved in salvaging metabolite S-adenosyl methionine ...

In MTAP-deleted tumor cells, the accumulating methylthioadenosine (MTA) increases sensitivity to PRMT5 inhibition, while binding with PRMT5 to form a novel MTAP-deleted cancer specific target ...

Citation: Study offers way to increase immune checkpoint inhibitor effectiveness in patients with MTAP-deleted cancers (2023, September 28) retrieved 23 May 2025 from https://medicalxpress.com ...

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial ...

We are excited to continue to explore this potential first-in-class combination in MTAP-deletion solid tumors and look forward to providing clinical program updates in 2025," said Darrin Beaupre ...